Farrell Simon, Pharm.D., serves as Chief Commercial Officer at Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). With over 25 years of experience in the pharmaceutical industry, Dr. Simon brings a proven track record of successful product launches, commercial strategy, and revenue growth. She holds a Doctor of Pharmacy degree from the University of Maryland School of Pharmacy and began her career in clinical pharmacy before transitioning into commercial leadership roles at major pharmaceutical companies. Prior to joining Trevi in 2023, Dr. Simon was Chief Commercial Officer at Axsome Therapeutics, where she spearheaded the U.S. launches of Auvelity for major depressive disorder and Sunosi for narcolepsy, driving significant market penetration and commercial success. Previously, as Senior Vice President of U.S. Commercial at Ironwood Pharmaceuticals, she led the linaclotide (Linzess) franchise to over $1 billion in annual net sales through innovative marketing strategies and payer access expansions. Her earlier roles included executive positions at Salix Pharmaceuticals and Abbott Laboratories, where she honed expertise in gastroenterology, neurology, and rare disease markets. At Trevi Therapeutics, Dr. Simon oversees all commercial functions, including market access, sales force readiness, and launch planning for the company's lead candidate, Haduvio (haduzodiac), which is poised for potential commercialization pending FDA approval. Her strategic vision positions Trevi to address unmet needs in chronic cough, leveraging her deep experience in CNS and respiratory therapeutics to build a high-performing commercial organization.